Researchers at Tohoku University in Japan have developed a novel antibody aimed at the aggressive HER2 positive subtype of breast cancer. The findings are reported in a study associated with the International Journal of Molecular Sciences.
HER2 positive breast cancer accounts for about one in five breast cancer cases. Tumor cells in this category display higher levels of the HER2 protein on their surfaces. This protein drives cell growth and division, and its overabundance is a key factor behind the heightened aggressiveness of HER2 positive tumors.
In laboratory settings, scientists produced a monoclonal antibody capable of neutralizing tumor cells that express the HER2 protein. Monoclonal antibodies are specially engineered proteins that identify and bind to precise targets with high precision.
The newly developed antibody shows selective action against HER2 positive cells by hindering their growth and division while sparing nearby healthy tissue. Researchers point out that conventional treatments like chemotherapy often lack this level of target specificity.
The next steps involve advancing this development into clinical trials. Researchers are also exploring the potential to create additional antibodies that target other cancer subtypes and indications.
Previous discussions have highlighted the importance of breast density testing and its role in guiding screening decisions.